Successful adalimumab desensitization after generalized urticaria and rhinitis.
Rodríguez-Jiménez
B
B
Allergy Unit, Hospital Universitario de Getafe, Getafe, Spain. alergologia.hugf@salud.madrid.org
Domínguez-Ortega
J
J
González-Herrada
C
C
Kindelan-Recarte
C
C
Loribo-Bueno
P
P
Garrido-Peño
N
N
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D012220:Rhinitis / Q000276:immunology / Q000628:therapy*; D014581:Urticaria / Q000276:immunology / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab